Objective: To identify preoperative clinical features that predict a durable improvement in renal function with renal artery stenting (RAS). Methods: Sixty-one patients with renal insufficiency (serum creatinine >1.5 mg/dL) underwent RAS for renal salvage. Patients were categorized as "responders" if estimated glomerular filtration rate (eGFR) at last follow-up was improved 20% or more over baseline. Patients with stable or worse renal function after RAS were labeled "non-responders." For the purpose of calculating changes in eGFR, patients on dialysis were represented by an eGFR of 10 ml/min/1.73 m 2 . Renal volume was estimated as kidney length ؋ width ؋ depth/2. Surgical revascularization of the renal arteries for ischemic nephropathy is associated with improved renal function in 43% to 80% of patients.
Surgical revascularization of the renal arteries for ischemic nephropathy is associated with improved renal function in 43% to 80% of patients. [1] [2] [3] [4] Moreover, retrieval of renal function after surgical revascularization has been associated with improved dialysis-free survival. 1 However, the benefits of surgical revascularization for ischemic nephropathy are achieved at considerable risk to the patient. Centers of expertise have reported mortality rates ranging from 4% to 7% for surgical revascularization for ischemic nephropathy, 1,2 whereas the nationwide mortality rate for renal artery bypasses performed for ischemic nephropathy is at least two-fold higher (18%). 5 Renal artery stenting (RAS) offers a lower risk alternative to surgical revascularization, but the response of renal function to RAS has been inferior to surgical revascularization. In three recent series, improved renal function after RAS was observed in a minority (23%-50%) of patients. [6] [7] [8] We surmise that the poor results for RAS are related to patient selection. Currently, there is a relative dearth of evidence-based guidelines to aid clinicians with patient selection for RAS. We hypothesize that there are clinical or renal morphologic features that discriminate patients who will benefit from RAS ("responders") from those who gain no benefit from the procedure ("non-responders"). Thus, the purpose of this study was to identify preoperative clinical features that predict a durable improvement in renal function with RAS.
METHODS
Study population and clinical data collection. This retrospective review reports the outcomes for patients with renal insufficiency (serum creatinine Ն1.5 mg/dL) who underwent primary RAS at the University of Texas Southwestern Medical School and its affiliated hospitals over a 9-year period ending July 1, 2008. Inclusion required a minimum of one month of postoperative follow-up and two serial visits for laboratory testing to determine the response of renal function to RAS. Exclusion criteria included nonatherosclerotic pathologies and secondary lesions after prior stenting. Seventy-four patients with a serum creatinine Ն1.5 mg/dL underwent RAS during the study period. Thirteen patients were excluded due to insufficient pre-or postoperative clinical and laboratory data for analysis (n ϭ 12) or concurrent nephrotoxicity (n ϭ 1), leaving a cohort of 61 patients for analysis. The study was approved by the Institutional Review Boards of the University of Texas Southwestern Medical School and the Dallas Veterans Affairs Medical Center.
Demographic, clinical, renal morphologic, and procedural data were collected. Average values for serum creatinine (mg/dL) and estimated glomerular filtration rate (eGFR) at pre-and postoperative time points were calculated from two to three clinic visits. The abbreviated Modification of Diet in Renal Disease formula was used to calculate eGFR: 186 x (serum creatinine) Ϫ1.154
Ϫ0.203 x (0.742 if female) x (1.210 if African American). 9 To permit calculations related to eGFR, patients requiring renal replacement therapy were designated as having an eGFR of 10 mL/min/1.73 m 2 . Average blood pressure (BP) and numbers of antihypertensive medications were quantified as described previously.
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Definition of renal function response. The primary outcome measure was renal function response to RAS. Patients were categorized as "responders" if the average eGFR at last follow-up was increased Ն20% over prestenting eGFR, which is based on the American Heart Association Reporting Guidelines and prior publications. 6, 7, 11 Patients with stable (Ͻ20% change in eGFR) or worsened renal function (Ն20% decrease in eGFR) after RAS were designated "non-responders" and analyzed as one group. A minimum of 1 month of follow-up was required for inclusion to permit stabilization of renal function after stenting.
Kidney morphometrics. Kidney morphometrics were obtained from preoperative contrast-enhanced computed tomography (CT) or magnetic resonance (MR) angiography. Prehydration was prescribed routinely prior to contrast-enhanced imaging, while pretreatment with mucomyst or bicarbonate infusion was employed selectively. Kidney measurements included pole to pole length, medial to lateral width, and anterior to posterior depth. Duplicate measurements were averaged for each kidney. Renal volume was estimated from these parameters [(kidney length) ϫ (width) ϫ (depth/2)], as validated and reported previously. 10, 12, 13 Statistical analysis. The primary end point of the study was renal function response to RAS. Categorical data were analyzed using 2 or Fisher exact tests. Continuous data were reported as medians and interquartile ranges (IQR). Comparisons of continuous data between groups were performed with Wilcoxon matched pairs tests and Mann-Whitney U tests. Stepwise multivariate logistic regression analysis was used to identify predictors of renal function response to stenting. Those variables that were significant (P Ͻ .05) on univariate analysis were included in the regression model. Survival was calculated according to the Kaplan-Meier technique, and survival curves were compared using the log-rank test. For all statistical analyses, the threshold for significance was .05. Statistical analysis was performed using SAS, version 9.13 (SAS Institute, Inc, Cary, NC).
RESULTS
Baseline characteristics. The study population consisted of 61 patients with a median age of 66 years (IQR, 60-73 years). Baseline characteristics (Table I) were typical of a patient population with advanced atherosclerosis. The cohort had moderate baseline renal insufficiency with a median serum creatinine of 1.8 mg/dL (IQR, 1.6-2.3 mg/dL), excluding patients receiving renal replacement therapy. The median eGFR was 34 mL/min/1.73 m 2 (IQR, 23-45 mL/min/1.73 m 2 ). Four patients (6.6%) were receiving renal replacement therapy prior to RAS. Prior to RAS, declining renal function was apparent in the cohort. The median change in preoperative eGFR was Ϫ0.46% per week, over a median preoperative interval of 9 weeks (IQR, 6-14 weeks).
Three patients (4.9%) had solitary kidneys due to prior nephrectomy. All patients had concurrent hypertension with a median preoperative systolic BP of 149 mm Hg (IQR, 140-179 mm Hg) and median diastolic BP of 75 mm Hg (IQR, 67-89 mm Hg) on a median of four antihypertensive medications (IQR, 3-5 medications).
Procedural details. Seventy-six renal arteries were stented in 61 patients (46 unilateral, 15 bilateral). One procedural complication was reported, consisting of a displaced stent that required endovascular extraction. Stented lesions had a median stenosis of 80% (IQR, 70%-88%) by arteriography. Embolic protection was employed in a minority of cases (n ϭ 2). Predilatation of the stenosis was required in 14 patients (23.0%) prior to stenting. All implanted stents were balloon expandable stents with a median stent diameter of 6 mm (IQR, 5-6 mm) and length of Cohort outcomes. The median follow-up for the cohort was 24 months (IQR, 16-33 months). Outcomes for the entire cohort, analyzed in aggregate, are outlined in Table II . As a group, renal function was not significantly improved by RAS. Of the four patients receiving renal replacement therapy prior to stenting, one was liberated from hemodialysis and three remained on dialysis. Five additional patients with stage V chronic kidney disease (median preoperative eGFR of 16 mL/min/1.73 m 2 ; IQR, 13-19) ultimately proceeded to dialysis during follow-up.
Despite a lack of improvement in renal function for the cohort, BP was significantly improved by RAS (Table II) . Both the median systolic and diastolic BP were significantly improved after stenting, and fewer antihypertensive medications were required for BP control.
Three patients were diagnosed with in-stent stenosis based on follow-up renal artery imaging at a median interval of 10 months (IQR, 7-10 months) post-stenting. None of the patients with restenosis experienced any change in renal function or BP control due to the restenosis and underwent prophylactic angioplasty to treat the radiographic finding.
Patient-specific outcomes. Although the cohort at large derived no improvement in renal function from RAS, a subset of 17 patients (27.9%) had a substantial improvement in eGFR over baseline after stenting. These patients were deemed "responders," according to our criteria. Nonresponders consisted primarily of patients with no significant change in their eGFR (n ϭ 27), although a subset (n ϭ 17) had worsened renal function after RAS. For responders, the median improvement in eGFR after stenting was 13 mL/min/1.73 m 2 (IQR, 10 to 18mL/min/1.73 m 2 ), whereas non-responders had a small decrease in eGFR (Ϫ3.0 mL/min/1.73 m 2 ; IQR Ϫ9 to 0 mL/min/1.73 m 2 ) at late follow-up. Compared with baseline, these changes represent a 47% improvement in eGFR for responders and a 13% decrement in eGFR for non-responders (P Ͻ .0001). Although the proportion of patients requiring renal replacement therapy at late follow-up was higher among non-responders (18.2%) than responders (nil), this difference was not statistically significant (P ϭ .09). The renal function response to stenting proved to be durable, as no early responders suffered sufficient deterioration in renal function to be recategorized as non-responders at late follow-up. In addition, long-term survival was not significantly different between responders and non-responders (Fig 1) .
A major focus of the analysis was identifying preoperative parameters that may distinguish responders from nonresponders and aid in patient selection. To that end, responders and non-responders were compared with univariate analyses (Table III) . Two major differences in responders and non-responders were identified. Responders had worse renal function at baseline, based on both serum creatinine and eGFR. Responders also had a steeper decline in renal function over the weeks prior to stenting. Indeed, the rate of decline of preoperative eGFR per week was 20-fold more precipitous among responders than nonresponders (Table III ; P Ͻ .0001). No other demographic or clinical factors differed significantly between responders and non-responders (Table III) .
Forty-three of 61 patients (70.5%) had sufficient preoperative renal imaging to permit measurements of renal morphology. Within the subset of patients with preoperative imaging, kidney length, width, depth, and volume for the ipsilateral (stented) kidneys and contralateral (un- The number at risk is provided for each time point. The standard error for responders and non-responders exceeded 10% at 78 and 108 months, respectively. There was no significant difference in survival between the two groups (log-rank test, P ϭ .35).
stented) kidneys were no different between responders and non-responders (Table III) . Of note, the proportion of patients receiving intravenous contrast for preoperative imaging was not significantly different between the responder and non-responder groups (58.8% vs 75%; P ϭ .23).
The subset of patients with worsened renal function (Ն20% decline in eGFR) after RAS was also examined for features to distinguish this group from other patients undergoing stenting. This analysis failed to identify demographic, clinical, or renal morphologic differences between patients with worsened renal function and the remainder of the cohort (Table IV, online only) .
Procedural details were examined for potential differences between responders and non-responders. The proportion of bilateral stenting procedures was higher among non-responders (27.3%) than responders (17.7%), but the difference was not significant (P ϭ .52). The severity of renal artery stenosis prior to RAS was not different between responders (80%; IQR, 70-90%) and non-responders (78%; IQR, 70-82%; P ϭ .08). Median stent diameter was similar between the two groups (responders vs non-responders ϭ 6 mm [IQR, 5-6 mm] vs 6 mm [IQR, 5-6 mm]; P ϭ .60), and stent length was identical (18 vs 18 mm; P ϭ .66).
Multivariate analysis was used to identify independent predictors of a favorable response of renal function to RAS. The two variables that were significant on univariate analysis, preoperative serum creatinine and rate in decline in preoperative renal function, were included in the multivariate model. Logistic regression analysis identified the rate of decline of renal function prior to stenting as the only independent predictor of improved renal function after RAS (odds ratio, 3.4; 95% confidence interval, 1.6-7.5; P ϭ .0019). There was no significant interaction between the two independent variables in the model. The C statistic for the model was .88, indicating an excellent ability to discriminate responders from non-responders. The Hosmer-Lemeshow goodness-of-fit test for the model was nonsignificant (P ϭ .11), indicating little departure from a perfect fit.
The relationship between the rate of change in preoperative renal function and outcome for RAS is depicted in Fig 2. Responders experienced a precipitous drop in eGFR over a median time interval of 12 weeks (IQR, 9-17 weeks) prior to stenting (Fig 2, A) . In contrast, non-responders had no deterioration in in eGFR over a median of 9 weeks (IQR, 6-12 weeks) before RAS (Fig 2, B) . From these data, we sought to identify a potential threshold slope in preoperative eGFR that could be used in patient selection for RAS. Using the median change in preoperative eGFR per week for the entire cohort (Ϫ0.46% per week) as a minimum threshold for patient selection for stenting would have correctly identified responders in 15 of 17 cases (Fig  3) . However, 15 of 44 non-responders (34.1%) also had a rate of decline in renal function that exceeded this threshold (Fig 3) . The sensitivity and specificity for this threshold were 0.88 and 0.66, respectively. The positive predictive value was 0.50, while the negative predictive value was 0.94. 14 For clinicians at the bedside, these guidelines are too non-specific to be helpful clinically in patient selection. The goal of the current study was to compare and contrast "responders" with "non-responders" to identify predictors of outcome that may facilitate patient selection. Our data showed that the rate of decline in preoperative renal function is a robust predictor of the response of renal function to RAS. Responders had a 20-fold more precipitous decline in preoperative renal function than non-responders (Fig 2, Table III ), which translated postoperatively into a durable recovery of renal function for responders.
Taking these results a step further, we sought to identify a threshold rate of decline in preoperative renal function that could be used in patient selection. Using the median change in preoperative eGFR over time in our study population (Ϫ0.46% per week) as a threshold would have been identified 15 of 17 responders correctly. However, 15 of 44 non-responders also had a decline in renal function that exceeded this threshold. The greater utility of this threshold may lie in identifying those patients who will not benefit from RAS. The high negative predictive value (0.94) of this threshold suggests that 94% of patients with a decline in preoperative eGFR lower than this threshold (ie, less rapid deterioration in renal function), will see little or no improvement in renal function after RAS. Although further validation of this threshold is required, we believe this criterion may have utility in patient selection. These data also suggest that longitudinal assessments of renal function are critical to patient selection for RAS, rather than basing patient selection for RAS on a single "snapshot" in time.
The relationship between decline in preoperative renal function and outcomes for renal artery revascularization is not a new concept. Dean and colleagues found that patients with more rapid deterioration in renal function prior to surgical revascularization of the renal arteries were more likely to experience an increase in eGFR after surgery. 15 In their analysis of the Cleveland Clinic experience with RAS for renal salvage, Kashyap et al reported a similar observation in a cohort of stented patients. 8 Neither Dean nor Kashyap proposed a threshold rate of change in preoperative eGFR for use in patient selection, which we believe would be particularly useful for clinicians.
Bilateral revascularization and unilateral revascularization of solitary kidneys were identified previously as clinical parameters that may portend a greater probability of retrieval of renal function, but the data are conflicting. Dean found that bilateral revascularization was strongly associated with improved renal function after surgical renal artery revascularization. 15 Kashyap found no association between bilateral RAS and outcome in his series. 8 Our observations echoed Kashyap's observations, as the 15 patients in our series who underwent bilateral stenting were non-responders. Patients undergoing bilateral stenting constituted a small minority (24.6%) in our series, so it remains unclear whether bilateral treatment is a predictor of outcome for RAS.
The proportion of renal function responders in the current series deserves comment. Twenty-seven percent of patients in our series were renal function responders, which is at the lower end of the spectrum of previously reported response rates. [6] [7] [8] This discrepancy may be explained, in part, by differences in the definition of a clinical response and the duration of outcome. For instance, 42% of patients were categorized as responders in Kashyap's series, but that study utilized a more liberal definition of renal function response (Ն10% improvement in eGFR) to define responders. Edwards reported that 50% of 26 patients treated for renal salvage had a Ն20% improvement in eGFR over baseline, but those data represent short-term outcomes assessed at 4 to 6 weeks postoperatively. By comparison, the current study reported late outcomes at a median follow-up of 24 months. Nolan reported a response rate of 23% at 1-year post-stenting, 6 which is more consistent with the results from the current study.
It is noteworthy that the predictor of renal function response identified in this study differs from those identified in our prior study on BP response to RAS. 10 In that study, we identified three predictors of a favorable BP response to stenting: (1) use of Ն4 antihypertensive medications; (2) preoperative diastolic BP Ͼ90 mm Hg; and (3) preoperative clonidine use. None of these variables was a predictor of renal function response in the current study. This finding suggests that different variables impact the outcome for RAS, depending on the clinical presentation for renovascular disease. It is important for clinicians to be cognizant of these differences when selecting patients for RAS.
Although the results of the current study confirm and extend observations from prior studies, there are limitations to the study that must be acknowledged. First, the current study cannot address the potential role of renal stenting in "stabilizing" renal function of some non-responders since there is no control group of patients with untreated renal artery stenosis for comparison. Second, preoperative duplexderived resistive indexes have been used in some studies to stratify responders and non-responders, 16 but those data were not available for the majority of patients in this series. As such, we cannot compare the relative predictive power of resistive indexes to the predictor identified in this study. Third, the lack of a comprehensive program of postoperative duplex surveillance in this series precluded an objective assessment of stent patency for the cohort. However, no early responders suffered sufficient deterioration in renal function on serial laboratory testing to be re-categorized as non-responders at late follow-up. This observation could be interpreted as evidence that any lack of renal function response in non-responders was unlikely to be a consequence of in-stent stenosis. Fourth, the use of an embolic protection device is a technical adjunct that may prevent parenchymal embolization during renal artery stenting and improve outcomes. 7, 17 Embolic protection was not used in the majority of cases in the current series, which could explain the higher proportion of patients experiencing a deterioration in renal function post-stenting, compared with other studies. 7 Finally, the small size of this series limited the statistical power of the analyses, which may have compromised our ability to identify other predictors of renal function response.
CONCLUSIONS
The current study found that a minority (27.9%) of patients responded to RAS with an improvement in renal function. A steep decline in preoperative renal function portends a higher likelihood of renal salvage from RAS among patients with renal insufficiency. We propose a threshold rate of decline in preoperative eGFR of Ϫ0.46% per week to discriminate responders from non-responders, although this threshold requires validation in a different patient population. If validated, incorporating this finding into patient selection may improve the outcomes for RAS. First, as an investigator of this same issue, our group at Wake Forest is currently focusing on trying to identify the kidney that is damaged beyond the capacity for a large vessel revascularization to result in significant functional improvement. As we all know, diabetes is a leading cause of "medical" kidney disease and diabetes affected 40% of the patients in your report. I did not see it listed in the covariates examined as a potential predictor of significant renal function response. Did your group examine diabetes in this way, and, if so, what were the results?
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Second, how many eGFR measures did you employ to define the rate of renal function decline? Was your measure a linearized measure of two points or a slope of multiple data points?
Third, in your manuscript, you suggest that your results are somewhat atypical (on the low side) as far as renal function response rates. They are actually perfectly consistent with weighted averages across the literature that we employ in our funding applications with an observed rate of improvement and deterioration of ϳ25%. Given the importance of renal function response to follow-up survival, did your group also analyze predictors of significant renal function deterioration during follow-up?
Fourth, your presentation detailed the finding that bilateral intervention was not a predictor of significant renal function response, refuting the previous work by Dr Dean and the findings (with regards to blood pressure) of the Scottish Newcastle group. Did you consider unilateral treatment to a solitary kidney bilateral treatment? Could you offer any thoughts on the lack of an effect observed for global renal revascularization? Furthermore, how did you deal with kidney volumes in a patient with two treated kidneys as far as using the data to predict renal function response?
Fifth, you present data with a median follow-up of 26 months and lasting response rate of 23%. What was the short-term response rate? Your presentation reported a very low rate of restenosis and no renal function or blood pressure effect in those patients. What was the observed fall-off rate in initial positive renal function response?
Finally, were you able to examine other potential predictive modalities such as renal duplex derived resistive index or measures of glomerular damage such as urinary albuminuria in your sample?
Congratulations, again, on your excellent presentation and I look forward to your answers. Dr J. Gregory Modrall. Thank you, Dr Edwards, for your comments and your insightful questions. I can't say enough about the contributions you and your group have made to this field, and I'm humbled to have you as a discussant.
In looking at the covariates, you correctly identified diabetes as a variable that we should have reported in our presentation. Diabetics were equally distributed between the responder and non-responder groups, so it appears that diabetes is not a predictor of response to renal artery stenting.
Your question regarding the technique for quantifying preoperative estimated GFR is important. For that analysis, we examined two time points for each patient-late pre-op and remote pre-op time points. For each time point, a minimum of two measurements of estimated GFR were used to calculate an average eGFR for that time point. For simplicity of reporting, we did not report the eGFR at intervals between these time points to plot a curve.
Your question about searching for predictors of significant renal function deterioration is also very important. You correctly point out that it is probably just as important to identify predictors of a failure to respond to stenting as it is to identify predictors of a favorable response. Unfortunately, we simply did not orient our analysis in that direction, but that's something we will add to the manuscript.
With regard to your question of how we handled those patients who had solitary kidneys, there were only two patients in the entire series that had a prior nephrectomy. With so few patients, it was apparent that these cases had minimal influence on the results regardless of how they were analyzed.
As for the statistical approach to incorporating kidney volumes for patients who underwent bilateral stenting into the analysis, there was no need for mixed modeling to incorporate both patient level and kidney level data into the multivariate analysis because kidney volume was not significant on univariate analysis. I will add, though, that the results did not differ based on whether an average of the two kidneys or individual kidney volumes were used in the analysis, as kidney volume was not a significant predictor in univariate analysis.
With regard to your question about the early versus late response rates, there were no early responders who then subsequently became non-responders based on late deterioration of renal function. This suggests that renal function responses to renal artery stenting are durable, and also suggests that there was no clinically significant restenosis that were not captured with postoperative clinical and radiologic follow-up.
Finally, with regard to resistive indicies and glomerular damage manifesting as albuminuria, this omission should be acknowledged as a major shortcoming of this study. Many of our patients were referred from elsewhere with duplex sonography results and proceeded directly to a secondary imaging study, so those data are incomplete and uninterpretable.
Again, I thank you for your insightful questions. 
